A randomized, double-blind, placebo-controlled, parallel-group, multicenter 12-week study assessing the efficacy and safety of AVE0010 in patients with type 2 diabetes not treated with antidiabetic agents.

Registry ID

EUCTR2007-005887-29

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Sanofi-Aventis Recherche & Développement

Start date

2008-04-30

Last update

2026-08-16

Conditions

• Type II diabetes

Summary

The primary objective of this study is to assess the effects of AVE0010 on glycemic control used in a two-step dose titration regimen in comparison to placebo in terms of HbA1c reduction (absolute change) over a period of 12 weeks in patients with type 2 diabetes not treated with antidiabetic agents.

Locations

• , , Belgium

View on source registry